BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9885802)

  • 1. Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues.
    Lauriero F; Pierangeli E; Rubini G; Resta M; D'Addabbo A
    Nucl Med Commun; 1998 Dec; 19(12):1127-34. PubMed ID: 9885802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 111In-octreotide scintigraphy in pituitary adenomas.
    Tofani A; Cucchi R; Pompili A; Carapella C; Crecco M; Mottolese M; Maini CL
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours.
    Acosta-Gómez MJ; Muros MA; Llamas-Elvira JM; Ramírez A; Ortega S; Sabatel G; Ramos C; de la Riva-Aguilar A
    Br J Radiol; 2005 Feb; 78(926):110-5. PubMed ID: 15681321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
    Losa M; Magnani P; Mortini P; Persani L; Acerno S; Giugni E; Songini C; Fazio F; Beck-Peccoz P; Giovanelli M
    Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands.
    van Royen EA; Verhoeff NP; Meylaerts SA; Miedema AR
    J Nucl Med; 1996 Sep; 37(9):1449-51. PubMed ID: 8790190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide.
    Tumiati MN; Facchi E; Gatti C; Bossi A; Longari V
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):98-100. PubMed ID: 9002761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
    Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
    J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
    Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor imaging in CNS tumours using 111In-octreotide.
    Maini CL; Sciuto R; Tofani A; Ferraironi A; Carapella CM; Occhipinti E; Mottolese M; Crecco M
    Nucl Med Commun; 1995 Sep; 16(9):756-66. PubMed ID: 7478408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
    Oppizzi G; Cozzi R; Dallabonzana D; Orlandi P; Benini Z; Petroncini M; Attanasio R; Milella M; Banfi G; Possa M
    J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic imaging of a TSH-producing pituitary adenoma associated with the "empty sella" by somatostatin and dopamine D2 receptor scintigraphy].
    Berger F; Meyer G; Weiss M; Pfluger T; Horn K; Tatsch K; Hahn K
    Nuklearmedizin; 2000; 39(1):42-5. PubMed ID: 10726258
    [No Abstract]   [Full Text] [Related]  

  • 17. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors.
    Panza N; Rambaldi PF; Battista C; Ambrosio G; Cascini GL; Schillirò F; Mansi L
    Biomed Pharmacother; 1999 Aug; 53(7):319-22. PubMed ID: 10472432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index].
    Görges R; Cordes U; Engelbach M; Bartelt KM; Haberern G; Hey O; Beyer J; Bockisch A
    Nuklearmedizin; 1997 Jun; 36(4):117-24. PubMed ID: 9289697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.
    Verhoeff NP; Bemelman FJ; Wiersinga WM; van Royen EA
    Eur J Nucl Med; 1993 Jun; 20(6):555-61. PubMed ID: 8339737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.